Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined
Xu‐Feng Zhang(First Affiliated Hospital of Xi'an Jiaotong University), Shishir K. Maithel(Broad Institute), Flavio G. Rocha(Memorial Sloan Kettering Cancer Center), Diamantis I. Tsilimigras(The Ohio State University Wexner Medical Center), Timothy M. Pawlik(The Ohio State University), George A. Poultsides(Stanford University), Kamran Idrees(Nashville Oncology Associates), Daniel E. Abbott(University of Cincinnati Medical Center), Ryan C. Fields(Washington University in St. Louis), Cliff Cho(University of Michigan), Xiaoning Wu(First Affiliated Hospital of Xi'an Jiaotong University)
Cited by 35
Related Papers
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
|Journal of Clinical Oncology|2009|390
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer
|Gut|2020|221
Future cancer research priorities in the USA: a Lancet Oncology Commission
|The Lancet Oncology|2017|209